Volume | 474,120 |
|
|||||
News | - | ||||||
Day High | 3.53 | Low High |
|||||
Day Low | 3.36 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Sutro Biopharma Inc | STRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
3.41 | 3.36 | 3.53 | 3.42 | 3.42 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3,764 | 474,120 | US$ 3.47 | US$ 1,645,412 | - | 2.005 - 6.13 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:17:19 | formt | 200 | US$ 3.51 | USD |
Sutro Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
208.46M | 60.95M | - | 153.73M | -106.79M | -1.75 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sutro Biopharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STRO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.75 | 3.935 | 3.30 | 3.60 | 604,698 | -0.24 | -6.40% |
1 Month | 5.62 | 5.88 | 3.30 | 4.53 | 1,136,286 | -2.11 | -37.54% |
3 Months | 4.30 | 6.13 | 3.20 | 4.53 | 1,021,977 | -0.79 | -18.37% |
6 Months | 2.75 | 6.13 | 2.005 | 3.98 | 943,785 | 0.76 | 27.64% |
1 Year | 4.58 | 6.13 | 2.005 | 4.17 | 699,352 | -1.07 | -23.36% |
3 Years | 20.41 | 23.70 | 2.005 | 7.16 | 558,873 | -16.90 | -82.80% |
5 Years | 10.26 | 28.30 | 2.005 | 9.30 | 423,363 | -6.75 | -65.79% |
Sutro Biopharma Description
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. |